Clinical Trial Update: GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study [Phase 1]

View source ↗

Summary

A Phase 1, single-arm neoadjuvant study evaluating GV20-0251 in combination with Sintilimab for patients with resectable head and neck squamous cell carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• GV20-0251
• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Squamous Cell Carcinoma HNSCC | Phase 1 | Status: RECRUITING